The historical rank and industry rank for Corline Biomedical AB's Net Margin % or its related term are showing as below:
OSTO:CLBIO'
s Net Margin % Range Over the Past 10 Years
Min: -1224.14 Med: -217.19 Max: 9.89
Current: -143.06
OSTO:CLBIO's Net Margin % is ranked worse than 55.9% of 941
companies
in the Biotechnology industry
Industry Median: -88.29
vs OSTO:CLBIO: -143.06
Corline Biomedical AB (OSTO:CLBIO) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Corline Biomedical AB Net Margin % Related Terms
Corline Biomedical AB Net Margin % Historical Data
* Premium members only.
The historical data trend for Corline Biomedical AB's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:CLBIO vs VRTX, REGN, ALNY: Net Margin % Comparison
For the Biotechnology subindustry, Corline Biomedical AB's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Corline Biomedical AB Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Corline Biomedical AB's Net Margin % distribution charts can be found below:
* The bar in red indicates where Corline Biomedical AB's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Corline Biomedical AB (OSTO:CLBIO) has a Net Margin % of -58.28% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Corline Biomedical AB and its competitors. According to the industry distribution chart, Corline Biomedical AB ranks #526 out of 941 companies in the Biotechnology industry, placing it in the top 55.9%.
Is Corline Biomedical AB's Net Margin % too high?
Corline Biomedical AB's current Net Margin % is -58.28%. Based on the distribution chart, Corline Biomedical AB ranks #526 out of 941 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Corline Biomedical AB has a GF Score™ of 43/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Corline Biomedical AB's Net Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Corline Biomedical AB ranks #526 out of 941 companies for Net Margin %. This places Corline Biomedical AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Corline Biomedical AB and its competitors. Corline Biomedical AB's current Net Margin % is -58.28%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Corline Biomedical AB stock overvalued right now?
Based on GuruFocus' analysis, Corline Biomedical AB (OSTO:CLBIO) is currently considered Significantly Overvalued. The stock's GF Value™ is kr4.92, compared to a current price of kr17.45 — trading 254.7% above its estimated fair value. The current Net Margin % is -58.28%. Corline Biomedical AB's overall GF Score™ is 43/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Corline Biomedical AB (OSTO:CLBIO), the current Net Margin % is -58.28% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Corline Biomedical AB (OSTO:CLBIO) Overvalued in 2026?
Based on GuruFocus' analysis, Corline Biomedical AB stock appears to be overvalued.
The current stock price of kr17.45 is trading 254.7% above its estimated GF Value™ of kr4.92.
GuruFocus considers Corline Biomedical AB to be Significantly Overvalued.
Key valuation signals for OSTO:CLBIO:
Net Margin %: -58.28%
GF Value™: kr4.92 vs. price of kr17.45 (254.7% above fair value)
No single metric tells the full story. See the OSTO:CLBIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Corline Biomedical AB offers customers in the medical technology industry and regenerative medicine as well as transplant clinics products to manage immune thrombosis. The company offers a proprietary surface treatment technology, Corline Heparin Surface (CHS), which can be used in combination with all commonly used implant materials such as polymers (plastics) and various metals, but also for equipment where blood circulation occurs outside the body.
43GF Score
Get the complete analysis for OSTO:CLBIO
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:CLBIO has been successfully added to your 
